How Biotech Developers Are Working Towards New Diagnostic Solutions to Combat Covid-19
Clinical development has been initiated on the test, which is designed to detect the activity of what are known as T-cells.
- Clinical development has been initiated on the test, which is designed to detect the activity of what are known as T-cells.
- In a recent US study , the presence of SARS-CoV-2-specific effector T-cells is likely a predictor of a person's ability to recover from severe COVID-19.
- Diagnostic solutions represented a whopping 111.1% growth year-over-year, with $2.4 billion in COVID-19 testing revenue boosting that segment to more than $4.3 billion in sales.
- Abbott's two tests are its BinaxNow rapid antigen test and its international counterpart, the PanBio COVID-19 Ag rapid diagnostic.